MiNK Therapeutics Files Definitive Proxy Statement

TL;DR

MiNK Therapeutics (MNKK) filed its proxy statement for 2025. Shareholders vote soon.

AI Summary

MiNK Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) on December 20, 2024, for its fiscal year ending December 31, 2025. The filing pertains to the company's annual meeting and related matters, with the report period ending January 17, 2025. MiNK Therapeutics, formerly AgenTus Therapeutics, Inc. until January 12, 2021, is a biotechnology company focused on biological products.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, executive compensation, and proposals to be voted on at the upcoming shareholder meeting, impacting their investment decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.

Key Numbers

• 20241220 — Filing Date (Date the DEF 14A was filed with the SEC.)
• 20250117 — Report Period End (The period for which the proxy statement information is relevant.)

Key Players & Entities

• MiNK Therapeutics, Inc. (company) — Registrant
• AgenTus Therapeutics, Inc. (company) — Former company name
• 20241220 (date) — Filing date
• 20250117 (date) — Report period end date

FAQ

Key Financial Figures

• $1.00 — e stock of listed companies be at least $1.00 per share. A listed company risks being

Filing Documents

• ny20039626x2_def14a.htm (DEF 14A) — 187KB
• ny20039626x1_pc01.jpg (GRAPHIC) — 523KB
• ny20039626x1_pc02.jpg (GRAPHIC) — 557KB
• 0001140361-24-050096.txt ( ) — 1674KB

From the Filing

DEF 14A 1 ny20039626x2_def14a.htm DEF14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to 240.14a-12 MiNK Therapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS MiNK THERAPEUTICS, INC. NOTICE OF SPECIAL MEETING OF STOCKHOLDERS Date January 17, 2025 Time 10:00 A.M., Eastern Time Webcast Live audio web conference at Address www.virtualshareholdermeeting.com/MINK2025SM Proposals 1. To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-10. 2. To consider any other business as may properly come before the Special Meeting or any postponement or adjournment of the meeting. Record Date You are entitled to vote if you were a stockholder of record on December 16, 2024. A list of stockholders entitled to vote will be open for examination by any stockholder for any purpose germane to the Special Meeting for ten days before the meeting during ordinary business hours at our principal offices at 149 Fifth Avenue, Suite 500, New York, NY 10010. It is important that your shares be represented at the Special Meeting. Therefore, whether or not you plan to attend the meeting virtually, please complete your proxy and return it to us. If you attend the Special Meeting virtually and wish to vote at the meeting, your proxy will not be used. You may also vote your shares over the internet or by telephone. Instructions for internet or telephonic voting are printed on your proxy card. By order of the Board of Directors, Jennifer S. Buell, Chief Executive Officer December 20, 2024 TABLE OF CONTENTS TABLE OF CONTENTS Page GENERAL INFORMATION ABOUT THESE PROXY MATERIALS AND VOTING 3 7 PROPOSAL 1 8 ADDITIONAL INFORMATION 11 APPENDIX A PROPOSED CERTIFICATE OF AMENDMENT A-1 i TABLE OF CONTENTS MINK THERAPEUTICS, INC. 149 Fifth Avenue, Suite 500 New York, NY 10010 Telephone: (212) 994-8250 PROXY STATEMENT For the Special Meeting of Stockholders To be Held on January 17, 2025 General The enclosed proxy is solicited by the Board of Directors (the "Board") of MiNK Therapeutics, Inc. (the "Company," "MiNK," "we" or "us"), for use at the Special Meeting of the Company's stockholders (the "Special Meeting") to be held on January 17, 2025, at 10:00 A.M. Eastern Time and at any adjournments thereof. Whether or not you expect to attend the meeting, please vote your shares as promptly as possible to ensure that your vote is counted. The proxy materials will be furnished to stockholders on or about December 20, 2024. Revocability of Proxy and Solicitation Any stockholder executing a proxy that is solicited hereby has the power to revoke it prior to the Special Meeting. Revocation may be made by voting over the internet (with only your latest internet vote counted), voting by telephone (with only your latest telephonic vote counted), attending the Special Meeting and voting the shares of stock, or by delivering a later-dated, properly executed proxy in accordance with the instructions below. Some of our directors, officers and employees may solicit proxies by telephone, e-mail, and in person. Record Date Stockholders of record at the close of business on December 16, 2024 (the "Record Date") will be entitled to receive notice of, attend and vote at the Special Meeting. Action to be Taken Under Proxy Unless otherwise directed by the giver of the proxy, the persons named in the form of proxy, namely, Jennifer Buell, our Chief Executive Officer, Robert Foster, our Director of Legal and Business Affairs, and Christine Klaskin, our Principal Financial and Accounting Officer, or any one of them who acts, will vote: FOR approval of an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended (the "Certificate of Incorporation"), to effect a reverse stock split of our issued and outstanding common stock at a ratio of 1-for-10 (Proposal No. 1—the "Proposal to Effect a Reverse Stock Split"). Vote Required; Quorum; Broker Non-votes As of the Record Da

View Full Filing

View this DEF 14A filing on SEC EDGAR